The 36-month beta value for CNSP is also noteworthy at 0.72. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CNSP is 2.92M, and at present, short sellers hold a 11.60% of that float. The average trading volume of CNSP on April 16, 2025 was 534.10K shares.
CNSP) stock’s latest price update
The stock price of Cns Pharmaceuticals Inc (NASDAQ: CNSP) has dropped by -25.23 compared to previous close of 1.28. Despite this, the company has seen a fall of -7.09% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-01 that Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme (GBM) for treatment of brain malignancies HOUSTON, TX / ACCESS Newswire / April 1, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the full year ended December 31, 2024 and outlined recent corporate and clinical development highlights. “Oncology drug development can be complex and challenging, but the GBM patients who live with this devastating condition in the shadow of a significant unmet medical need keep us motivated and determined to succeed.
CNSP’s Market Performance
Cns Pharmaceuticals Inc (CNSP) has seen a -7.09% fall in stock performance for the week, with a -68.73% decline in the past month and a -82.16% plunge in the past quarter. The volatility ratio for the week is 18.31%, and the volatility levels for the past 30 days are at 16.87% for CNSP. The simple moving average for the past 20 days is -44.27% for CNSP’s stock, with a -91.48% simple moving average for the past 200 days.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -66.96% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.88% of loss for the given period.
Volatility was left at 16.87%, however, over the last 30 days, the volatility rate increased by 18.31%, as shares sank -73.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -80.10% lower at present.
During the last 5 trading sessions, CNSP fell by -7.09%, which changed the moving average for the period of 200-days by -98.85% in comparison to the 20-day moving average, which settled at $1.7174. In addition, Cns Pharmaceuticals Inc saw -84.10% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CNSP
The total capital return value is set at -2.41. Equity return is now at value -1703.39, with -285.68 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -52.48. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -924.44.
Currently, EBITDA for the company is -14.9 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.42.
Conclusion
In summary, Cns Pharmaceuticals Inc (CNSP) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
